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Abstract: 
Cocaine-related deaths have increased since the early 1990s in Europe, 
including the UK. Being multi-factorial, they are difficult to define, detect 
and record. The European Monitoring Centre for Drugs & Drug Addiction 
(EMCDDA) commissioned research to: describe trends reported to Special 
Mortality Registries (SMRs) and General Mortality Registers (GMRs); 
provide demographic and drug-use characteristic information of cases; and 
establish how deaths are identified and classified. A questionnaire was 
developed and piloted amongst all EMCDDA Focal Point experts/SMRs: 19 
(63%) responded; nine countries provided aggregated data. UK GMRs use 
cause of death and toxicology to identify cocaine-related deaths. 
Categorisation is based on International Classification of Diseases (ICD) 
codes. SMRs use toxicology, autopsy, evidence and cause of death. The 
cocaine metabolites commonly screened for are: benzoylecgonine, 
ecgonine methyl ester, cocaethylene and ecgonine. The 2000s saw a 
generally accelerating upward trend in cases, followed by a decline in 
2009. The UK recorded 2700-2900 deaths during 1998-2012. UK SMR data 
(2005-9) indicate:  25-44 year-olds account for 74% of deaths; mean age 
= 34 (range 15-81) years; 84% male. Cocaine overdoses account for two-
thirds of cases; cocaine alone being mentioned/implicated in 23% in the 
UK. Opioids are involved in most (58%) cocaine overdose cases.    
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Glossary  
ATS  Amphetamine-type stimulants 
COD  Cause of death 
DRD   Drug-related death  
EMCDDA  European Monitoring Centre for Drugs and Drug Addiction  
GHB/GBL Gammahydroxybutyrate/Gammabutyrolactone 
GMR   General Mortality Register  
ICD-10  International Classification of Diseases and Related Health Problems 10th 
Revision  
‘Legal highs’ Licit drugs (chiefly stimulants such as cathinones, synthetic cannabinoids, etc. 
which may or may not have become regulated/controlled during the time-period 
examined by this project)  
MDMA  Methylenedioxymethylamphetamine 
NFP   National Focal Point  
NPS  Novel Psychoactive Substances 
NPSAD  National Programme on Substance Abuse Deaths 
PM   post mortem (autopsy) 
SMR   Special Mortality Registry  
UK   United Kingdom  
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 2
Introduction   
 
There has been increasing prevalence of cocaine use in some countries, and indications of 
increased number of cocaine deaths in some European countries up to the end of the first 
decade of the present century (in excess of 1,000 in 2007–8). Deaths were still at high levels in 
2011, at least 475 deaths in 17 countries, (EMCDDA, 2011; 2013a, 2013c), and at least 800 
were reported from 27 countries in 2013 (EMCDDA, 2015:45). In addition, there is evidence of a 
considerable burden of morbidity related to cocaine use in Europe (Mena et al., 2013; 
EMCDDA, 2013b, 2014). High mortality among cocaine users has been documented in different 
parts of the world, including Europe (Degenhardt et al., 2011; Barrio et al., 2013; Pavarin, 2013; 
de la Fuente et al., 2014). 
 
In the wider context, other factors have been shown to be related to cocaine-related deaths, 
these include a: positive correlation with ‘last year’ use of cocaine powder, number of offenders, 
and number of seizures, but negatively with price (Schifano and Corkery, 2008). Furthermore, 
such deaths are correlated positively with the numbers of crack offenders and seizures, but 
negatively with crack purity and price. 
 
Cocaine-related deaths are underestimated as they are more difficult to define, detect and 
record as such in mortality registries compared to, for instance, to heroin-related deaths - more 
particularly in some countries’ General Mortality Registers (GMRs) due to coding practices. The 
characteristics of cocaine deaths are multi-factorial (socio-demographics, toxicology, 
circumstances and mechanism of death), and are often different from opiate/opioid deaths and 
may not be collected by GMRs (Corkery, 2012; EMCDDA, 2013a).  
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 3
 
A project was commissioned to provide better information on the numbers and characteristics of 
cocaine-related deaths in Europe, to complete and deepen the information usually provided on 
drug overdose deaths (drug-induced deaths) to the European Monitoring Centre for Drugs & 
Drug Addiction (EMCDDA, 2010). This element complements the current routine data collection 
on drug-induced deaths by the EMCDDA, which provides only limited information on cocaine-
related deaths. The project attempted to establish how cocaine deaths are identified and 
classified, and gauge the level of, and possible reasons, for under-reporting. It is a seminal 
study in the context of understanding European cocaine deaths, providing fundamental 
information on such events generally, including causes and mechanisms of death, case 
demographics, substances involved, and case identification. 
 
This paper focuses on the UK, presenting sources of information used to collect data, and 
updates information on trends in cocaine-related deaths reported from 1998 to 2012. It 
discusses the (public) health implications and the gaps in data currently available, to inform 
future data collection, analysis and research.  
 
Methodology  
 
This paper draws on data collected as part of an EMCDDA project aimed to describe the trend 
in numbers of cocaine-related deaths reported to Special Mortality Registers (SMRs) (or GMRs 
where relevant) (Corkery, 2012). It also uses insights from a complementary study on cocaine-
related hospital emergency admissions (Mena et al., 2013) and other published data.  
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 4
Two sources of information were used in the UK context. First, all three UK GMRs (the Office for 
National Statistics (ONS) covering England and Wales; the General Register Office for Scotland 
(GROS), part of the National Records of Scotland (NRS); the General Register Office for 
Northern Ireland (GRONI) and the Northern Ireland Statistics & Research Agency (NISRA) 
extract deaths related to poisonings by drugs, medicaments, etc. using ICD-10 codes (WHO, 
1992, 2010) for adding to special databases set up to monitor DRDs (Christophersen et al., 
1998). Text searches of the wording of the medical cause(s) of death are then employed to 
assign deaths to specific classes of drugs or specific substances as listed in their annual 
publications on such fatalities (NISRA, 2016; NRS, 2016; ONS, 2016). The case definition used 
to extract the cocaine-related cases was ‘all cases with cocaine mentioned in the cause of 
death’. Only published statistics were accessed. 
 
The second source used was the UK SMR – the National Programme on Substance Abuse 
Deaths (NPSAD), based at St George’s University of London. The Programme receives 
information from coroners on a voluntary basis on deaths related to drugs in both addicts and 
non-addicts in England and Wales, Northern Ireland, the Channel Islands and the Isle of Man. 
From 2004 to 2011 information was also received from the Scottish Crime and Drug 
Enforcement Agency, and from 2004 onwards from the General Register Office for Northern 
Ireland. Since 1997 details of more than 30,000 deaths have been received. The average 
annual response rate from coroners in England and Wales to NPSAD during the period 
focussed on in this study, i.e. 2005-9 was between 89% and 95% (Ghodse et al., 2010). 
 
To be recorded in the NPSAD database as a drug-related death, at least one of the following 
criteria must be met: (a) presence of one or more psychoactive substances directly implicated in 
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 5
death; (b) history of dependence or abuse of drugs; or (c) presence of controlled drugs at post-
mortem (Corkery et al., 2014). Internal analysis by the NPSAD team in 2009 indicated that for 
deaths which occurred in England in 2007 and 2008, 47.7% met all three criteria, between 
49.3% and 81.5% met at least two criteria, and between 1.7% and 11.3% met only one criterion. 
These proportions were similar in both years. The basic approach used by the Programme to 
identify cases involving specific substances is a text search of the cause of death field. 
However, where a death is described as “multiple drug overdose” (or similar wording) 
information in the text of the coroner’s verdict may be useful for identification of specific 
substances involved. In addition, reference may be made to the autopsy and/or post mortem 
toxicology (PM) reports, with special attention being paid to the concentrations of relevant 
substances and/or their metabolites. These data, together with the coroners’ verdicts are used 
in the allocation of ICD-10 codes. For further information see Corkery et al. (2014). Two 
categories of cases were extracted from the NPSAD database: first, ‘all cases with cocaine 
mentioned in the cause of death’; and second ‘all cases with a positive toxicology for cocaine 
and/or its metabolites, whatever the cause of death’. The data from the GMRs and NPSAD are 
not directly comparable but do complement each other; the key differences between the ONS 
and NPSAD are described in Table 7 of Stephenson and Richardson (2014). 
  
Trend data presented here for the period 1998-2012) extend the data presented in the formal 
EMCDDA project report (Corkery, 2012). For all cases with cocaine mentioned in the cause of 
death, the total numbers of cases are given for any cocaine combination and whether cocaine 
was the sole substance. For NPSAD cases retrieved for the period 2005-9 with cocaine 
mentioned as a cause of death, the gender, age-group, and detailed toxicology findings were 
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 6
recorded (i.e. other substances identified). Information on whether the death was overdose 
(toxicity, intoxication, poisoning, etc.) or not overdose related was also retrieved. 
  
Part I of the Cause of Death on the death certificate or Medical Certificate of Death  (for an 
example of the latter, see Figure 1) should record the causal chain of morbid conditions that led 
to death, beginning with the condition most proximate to death on line (a) and working 
backwards to the initiating condition. The lines (a) to (c) in Part I are connected by the phrase 
‘due to, or as a consequence of’. Part I is designed to facilitate the selection of the underlying 
cause of death when two or more causes are recorded on the death certificate. Part II seeks 
other conditions that the certifier believed contributed to death, but were not in the causal chain. 
There can be an overlap between these categories in terms of the role which cocaine plays, e.g. 
post mortem (PM) toxicology reveals a lethal level of cocaine which causes death by poisoning. 
Many cases meet both criteria. However, cocaine may be detected through PM screening or 
analysis but at ‘trace’ levels without having contributed to the death, e.g. a car passenger who 
has consumed cocaine some time before being killed in a fatal road traffic accident.  
 
< Figure 1 about here > 
 
In order to establish whether or not any changes in trend were statistically significant or not 
regression analysis was undertaken using Joinpoint Trend Analysis Software Desktop version 
4.2.0.2 (http://surveillance.cancer.gov/joinpoint/). This statistical software permits the analysis of 
continuous linear trends with change points, i.e. joinpoints, to test whether an apparent change 
is statistically significant. This approach has been primarily used in cancer research, but has 
also been employed to look at trends in opioid analgesic and heroin-related deaths (Warner et 
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 7
al., 2014), and methadone-related overdose deaths (Wunsch et al., 2013), and excess mortality 
in cocaine users (de la Fuente et al., 2013). 
 
Results  
 
General trends and key findings 
 
Between 1998 and 2012, the period for which data were available for this study, there were 
2728 cases of deaths where cocaine was mentioned in the cause of death, registered in the UK 
by the 3 GMRs. A third (845; 31%) of these deaths had cocaine only mentioned (Table 21).  
During the same period, the SMR was notified of 2907 relevant cases where cocaine was 
implicated in the cause of death, of which 510; 17.5% had only cocaine mentioned. There were 
4100 cases received by the SMR where cocaine was recorded in the PM toxicology (of which 
333; 8.1% (range 3.0-9.6% over the period examined) were sole mentions). Over the period 
1998-2012, 87% of cases where cocaine was implicat d in death were regarded, in terms of 
underlying cause of death, as poisonings or overdoses according to ICD-10 codes.  
 
Trends 
 
GMR. Figures for the number of registered deaths published (NRS, 2016 for Scotland; NISRA, 
2016 for Northern Ireland; ONS, 2016 for England & Wales) by the three GMRs covering the UK 
show that any mentions of cocaine in the medical cause of death field on the death certificate 
totalled 2728 between 1998 and 2012. Such mentions generally rose year on year from 1998 
(n=69) to 2008 (n=325), but subsequently fell in 2011 (n=171) before increasing slightly in 2012 
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 8
(n=191) - see Table 2. This pattern was echoed by sole mentions. At the UK level, the number 
of sole mentions rose from 28 in 1998 to 101 in 2008, but fell to 37 by 2011, rising again to 42 in 
2012. The ratio of any to sole mentions of cocaine on UK death certificates during the period 
1998–2012 averaged 3.23:1 (2728/845) (range 2.20:1 to 4.62:1). The proportion of cases 
accounted for by sole mentions of cocaine in the cause of death field on UK death certificates 
averaged 31.0% (range 21.6-45.5%) over the period 1998-2012. 
 
SMR (NPSAD). In total, 2907 cocaine-related deaths occurring in 1998-2012 were notified to 
NPSAD by September 2013. The number of cases in which cocaine was implicated in the 
cause of death (for any type of cocaine-related DRD) rose from 83 in 1998 to 263 in 2002, 
before falling in 2004 but then peaking at 321 in 2007, decreasing to 156 by 2010, increasing in 
2011 (n=167) and falling again in 2012 (n=137). In respect of sole mentions, this same pattern 
obtained: the number rose from 8 in 1998 to 67 in 2008, but fell to 29 by 2012 (geographical 
coverage was poorer in the first few years of the Programme’s operation, which may account for 
some of this difference). The overall ratio during this p riod of any to sole mention was 5.70:1 
(2907/510) for cause of death (range 10.38:1 to 3.89:1). The overall proportion of sole cocaine 
mentions in the cause of death during the period 1998-2012 was 17.5% (range 9.6-25.7%). 
 
A total of 4100 deaths in which PM toxicology reports had any mention of cocaine were notified 
to NPSAD in the period 1998-2012. Such cases generally rose year on year from 1998 (n=83) 
to 2007 and 2008 (n=476), but subsequently fell to 242 in 2012. In respect of sole mentions, a 
similar pattern was present, rising from 8 in 1998 to plateau about 36–37 in 2005–7 but falling to 
10 by 2012. The overall proportion of sole cocaine findings in PM toxicology during the period 
1998-2012 was 8.1% (range 3.0-19.6%). 
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 9
 
< Table 1 about here > 
 
Depending on the data source, the peak in cocaine-related deaths occurred in either 2007 
(SMR) or 2008 (GMR). (The SMR uses the year of occurrence of death, whereas the GMRs 
report year of death registration.) Overall, a consistent pattern emerges from a comparison of 
the GMR and SMR trend figures (Figure 1).  
 
< Figure 12 about here > 
 
The results of Joinpoint regression analyses indicate that all six datasets investigated have a 
single joinpoint (Figure 2). Five out of the six joinpoints occurred in 2007 or 2008, only that for 
the SMR any cause of death mention is outside this period (2002). All these results are 
statistically significant (p < 0.05). See Table 2 for full details. 
 
< Figure 23 about here > 
 
< Table 2 about here > 
 
Key demographic characteristics 
 
Detailed demographic and other information are not published by the UK GMRs in respect of 
specific substances. The key characteristics for UK SMR cases in 2005-9 where cocaine was 
mentioned in the cause of death are given in Table 3. The main findings are: the mean age at 
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 10
death during the period was 34.3 years (range 15.6 to 81.3, standard deviation = 9.0). About 
89% were aged less than 45 years old, 56% were less than 35 years old. The majority were 
male (84%); and where ethnicity was known, the majority (88%) were White. Where information 
was available, 49% were employed, 54% lived with others, 82% had a history of drug 
use/addiction, and at least 7% of the general sample weresample was known to be injectors. 
 
<Table 3 about here> 
 
Underlying cause of death  
 
Out of the 1234 deaths during 2005-9 which involved cocaine in the cause of death, 1082 
(87.7%) were ascribed an underlying cause as a poisoning or overdose (Table 4). Of the 
remaining 152 cases, about 14 (1.1%) could be described as “general medical condition”, 
together with 21 (1.7%) having cardio-vascular and related problems, hanging 36 (2.9%), 
injuries 10 (0.8%), mental & behavioural disorders 51 (4.1%), drowning/falls 3 (0.2%), and road 
traffic accidents 5 (0.4%).      
 
<Table 4 about here> 
 
Substances implicated 
 
The mean number of post mortem drugs was 3.4, underlining the role of poly-substance use. In 
the majority of cases, opiate/opioids (alone or in combination with other substances) are the 
main feature of cocaine-related DRDs reported to the UK SMR: implicated in 58.2% of cause of 
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 11
death cases in 2005-9 (Tables 5 and 6). Other key substances implicated were alcohol (30% of 
cases), drugs for anxiety/insomniahypnotics/sedatives (mainly benzodiazepines, especially 
diazepam) (18%), drugs for depressionanti-depressants (9%), MDMA (5%), and amphetamines 
(5%). The most frequent combinations of substances (Table 6) involve alcohol, medications 
(excluding opiates/opioids), opiate/opioids, drugs for anxiety/insomniahypnotics/sedatives, and 
other recreational drugs (amphetamines, ecstasy, etc.). More recently, Novel Psychoactive 
Substances (NPS) have been seen in cocaine-related deaths; during the period 2005-9 the 
NPS concerned were piperazines. 
 
<Table 5 about here> 
 
<Table 6 about here> 
 
Identification and classification of reported cases 
 
The UK GMRs and SMR distinguish cocaine poisonings from other types of deaths. Poisonings 
and somatic (i.e. those relating to the body as opposed to mental and behavioural disorders) 
deaths overlap; it can be difficult to distinguish between them. Apart from cocaine itself, the 
principal metabolites commonly identified or screened for are: benzoylecgonine, ecgonine 
methyl ester, cocaethylene and ecgonine. The products of combustion can be a means of 
distinguishing smoked cocaine/crack from other modes of intake. However, toxicologists are not 
usually looking for such products. Information on the use of crack immediately prior to death 
usually comes from police examination of the death scene and/or witness statements.  The 
GMRs and SMR do not distinguish crack from powder cocaine in their publications. 
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Discussion  
 
This paper presents data on what we believe to be the largest number of cocaine-related deaths 
reported to date, drawing on both GMR and SMR records.  Whilst the extent of overlap between 
the two can be seen in respect of case definitions (Corkery, 2008), the extent to which 
identification of identical cases for specific drugs occurs can only be established by a dedicated 
study matching records for individual decedents. Factors which would have to be taken into 
account include: geographical coverage/reporting compliance; degree of ambiguity over the 
contribution of index drugs in cause of death described as ‘multiple drug overdose’, etc.; 
availability of detailed toxicology; under-identification of non-overdose deaths involving index 
drugs. 
 
Case identification 
 
In many cases, it is difficult to ascertain if a death was primarily due to cocaine poisoning, or 
whether it was due to a combination of substances, or the result of a pre-existing health 
condition precipitated by cocaine use. Compared to the UK, it has been unclear how cocaine 
deaths are identified in Europe. In particular, deaths occurring shortly after, and induced by, 
cocaine use, but which are not poisonings in the strict sense (i.e. overdoses), may not have 
been identified as induced by cocaine, and therefore are not reported (EMCDDA, 2007:19-20). 
The EMCDDA study found a range of approaches is used to retrieve cocaine-related cases 
from mortality registries (Corkery, 2012). There are complexities around variation in ICD coding, 
PM investigation, as well as the identification and reporting of cases in the first instance, e.g. 
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 13
distinguishing between clearly direct causality and other factors in particular types of cases (e.g. 
accidents).  Clearly, the lack of consistency in the definition of cocaine-related deaths by UK 
GMRs and SMRs, as well as databases across Europe makes some  inferences from data 
unreliable, as well as the aggregation of data and between-country comparisons.  Two of the 
three UK GMRs do not have access to post mortem toxicology, and the third only has some 
indication from pathologists as to possible drugs implicated (NRS, 2015). A wider range of 
factors is used by NPSAD, facilitating greater flexibility in approach: toxicology, autopsy, 
evidential information and cause of death.  
 
Representativeness 
 
Levels of under-identification and reporting cannot be gauged without undertaking further 
investigations to establish in detail the full range of reasons for under-reporting and their extent. 
However, NPSAD has been receiving access to all Northern Ireland drug poisoning deaths 
data. Some information is available on comparisons b tween Scottish Crime & Drug 
Enforcement Agency (SCDEA) and the Scottish GMR (now NRS) data for 2006 deaths. A core 
number of 321 deaths were counted by both the GMR and SCDEA; 100 deaths were counted 
by the GMR but not by SCDEA; and 53 cases were counted by SCDEA but not by the GMR 
(see Annex B of NRS, 2016). An audit of coronial files found that 3-4% of relevant cases had 
not been reported to NPSAD (Ghodse et al., 2010).  
 
One cannot simply add together the figures from GMRs and SMRs to establish the absolute 
number of cocaine-related deathsDRDs. The extent of overlap between cases recorded by the 
UK GMRs and NPSAD is not known in respect of drug-induced deaths generally nor for 
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cocaine-related deaths DRDs specifically. However, it is known that there are benefits in using 
these two different but complementary sources. They can each be used to cross-check or 
validate the findings of the other (i.e. triangulation). They are not alternatives since they have 
different functions. 
 
It would be beneficial to both the GMRs and NPSAD to be able to exchange information on 
named individuals on a regular and routine basis so that all relevant cases are identified, and 
thus both databases made more complete and accurate. The extent of overlap between them 
needs to be established. However, legislation restricts the way in which the GMR for England & 
Wales can share information with non-Governmental bodies; this limits the extent to which 
information can be exchanged between the two bodies. For ad hoc studies it is necessary for 
the SMR to register that specific project as a medical study.  Consideration could be given to 
see if such an arrangement could be extended to the surveillance work as a whole, or to an 
alternative mode of working. For this reason, we did not compute rates of cocaine-related 
mortality which could be misleading as the reporting systems differ and make it difficult to 
compute sufficiently robust rates at the population level. This allows trends over time to be 
observed, but does not risk misleading readers with estimates whose precision is open to 
question.  
 
For the most part, it is difficult to compare the data provided by one country with that from 
another for several reasons: (a) different types of data sources from registries with different 
roles, purposes and nature; (b) underlying differences in the data-items collected; (c) different 
definitions of DRDs, even where based on ICD-10 codes there are varying approaches; (d) 
different criteria used to define cocaine-related DRDs; (e) varying lengths of time for which data 
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are available; and (f) delays in publishing data. It is possible to look at trends over time within a 
country/region, but even then consistency of data may vary over time in terms of geographical 
coverage (e.g. the UK SMR), quality of data reported, and level of detail recorded. These are 
issues common to previous EMCDDA data-collation exercises (e.g. Wirl, 2010).  
 
Trends 
 
During the 15-year period examined here (1998-2012), a considerable number of deaths was 
identified in the UK by both the GMRs (2728 death registrations) where cocaine was mentioned 
in the cause of death, and by the SMR (a minimum of 2907 deaths occurring) where cocaine 
was involved in the death. Such deaths accounted for about 5.23% of poisoning as an 
underlying cause in GMRs (using a broad definition of drug) and 10.43% of SMR deaths 
involving psychoactive substances in respect of UK DRDs. This constitutes a considerable 
health burden and a significant number of premature deaths that are largely preventable. 
    
In Europe during the 2000s there was generally an increasing upward trend in cocaine-related 
deaths, followed by a decline in most countries (EMCDDA, 2011). However, the latest reports 
from NPSAD indicate a stabilisation in terms of cocaine deaths in 2011 (Corkery et al., 2014), 
but an increases between 2012 and 20134 in England (Claridge & Goodair, 2015, 2017). The 
UK GMR death registrations in 2011-15 indicate a rise in such deaths (NISRA, 2016; NRS, 
2016; ONS, 2016). The decrease after ~2008 is consistent with morbidity data in the UK (Mena 
et al., 2013; PHE, 2014). Although new presentations for treatment in England showed a 
continuous decline for primary crack use from 2007/8 to 2013/4, such notifications for cocaine 
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show a continuous rise from 2011/2 to 2013/4 (PHE, 2014). These patterns are replicated at a 
UK level (Burton et al., 2014). Close monitoring is still required.  
 
The patterns in UK cocaine-related DRDs need to be set in a wider context. Cocaine-related 
mortality could also be related to a wider set of indicators, as done a number of years ago for 
the UK (Schifano and Corkery, 2006, 2008). Part of the recent decline apparent in some 
countries (EMCDDA, 2013a), may be related to a decline in cocaine purity and/or a shift to 
using alternative stimulants, including ‘legal highs’ (Corkery, 2012; EMCDDA, 2013b). The UK 
street price of cocaine powder seized by law enforcement agencies fell from £60 per gram in 
2000 to £40 in 2008 and remaining at that level through to 2013 (Burton et al., 2014). However, 
the lower prices are probably due to the poorer quality of the cocaine. The mean purity of 
powder cocaine seized by the police in England & Wales fell from 33% in 2007 to 20% in 2009 
before rising again to 38% in 2013; the purity of 'crack' cocaine is reported to have fallen during 
the same period from 52% to 27% in 2009 before rising to 36% in 2013 (Burton et al., 2014). 
‘Last year ‘use of powder cocaine amongst 16–59 year-olds in England & Wales fell 
from 3.0% in 2008/9 to 1.9% in 2012/13 before rising to 2.3% in 2014/5 (Lader, 2015). The 
number of cocaine seizures in England & Wales peaked in 2008/9 and that for crack in 2007/8 
since when both showed declining trends to 2012/3 with a stabilisation in 2013/4 (Dhani, 2014). 
The quantities seized fell for cocaine from 2003 to 2009/10, recovered slightly in 2011/2, fell 
back in 2012/3 but recovered in 2013/14 to a level similar to that in 2007/8; for crack it fell back 
in 2008/9 before rising in 2009/10, fell in 2011/2, rising again in 2012/3 and 2013/4.  
 
There is now emerging evidence of a large problem of cocaine-related morbidity leading to 
hospitalisation and emergency visits (Mena et al., 2013). Chiefly involving males and young 
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patients (15-29 years old), they appear to follow patterns similar to those in cocaine DRDs in 
recent years. It has even been proposed that the fall in ecstasy and cocaine-related deaths in 
the United Kingdom since 2008 may have been as a result of users switching to ‘legal highs’ 
with the suggestion that this may have had an unintended harm reduction effect (Bird, 2010). 
 
Demographic characteristics 
 
The majority of cocaine-related deaths in 2005-9 reported to NPSAD occurred in the 20–24 to 
45–49 years age-groups (minimum 15, maximum 81). Mean age at death for these cocaine 
cases is typically in the late 20s or early 30s, much younger than the mean commonly reported 
by the GMR using the EMCDDA Standard (41 years according to 2012 reporting) (i.e. all 
overdose deaths, accounted for mainly by opioid-related cases). Males accounted for 84% of 
cases, broadly in line with the general findings for UK deaths reported to the EMCDDA; this 
proportion is higher than the approximately 75% usually seen for ‘typical’ SMR cases in 2012. 
Half (36%) were unemployed compared to 52% of NPSAD deaths in 2012. Higher rates of last 
year powder cocaine use are higher in the groups with the lowest household income category of 
< £10k (typically those receiving social benefits/unemployment benefits) or at the other extreme 
those with a household income >= £50k (Home Office, 2013). A higher proportion of cases in 
the present study (54%) were living with someone else compared to 2012 NPSAD cases (44%). 
Cocaine fatalities (82%) had a considerably higher occurrence of having a history of drug use 
than NPSAD cases in 2012 (67%). A wider range of ethnicities died from cocaine use during 
this period (88% White) compared to those recorded for NPSAD cases in general in 2012 (97% 
White) (Corkery et al., 2014). 
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Characteristics of deaths 
 
The vast majority (88%) of SMR deaths where cocaine was involved in the death were regarded 
as poisonings or overdoses involving this substance and/or its metabolites; similar to that found 
for NPSAD cases in 2012 (Corkery et al., 2014). Some 13% of cases had a reported pre-
existing cardiovascular/cardiopulmonary condition, with 22% developing primarily cardiac and 
pulmonary medical conditions, reflecting the dangers already known about cocaine (see Table 
7). Regular cocaine use can increase systolic blood pressure, aortic stiffness and left ventricular 
mass; these are well-recognised as risk factors for premature cardio-vascular events (Kozor et 
al., 2014).   
 
More individuals experimenting with the drug is a cause for serious concern, especially those 
with underlying coronary artery disease as it increases double product (heart rate x systolic 
blood pressure) and myocardial oxygen demand (Howard et al., 1985). Of note in this context is 
coronary atherosclerosis - particularly of the left anterior descending coronary artery (Darke et 
al., 2006); this is because a higher proportion of the minority of subjects at risk of acute cocaine 
medical sequelae and fatalities (genetic causes, such as fully or partially expressed congenital 
long QT syndrome, may play a role; Karch, 2005) will be more likely to be self-administering the 
compound (Webb et al., 2003). Furthermore, greater availability of cocaine formulations means 
that some consumers may find it easier to enter a chronic consumption pattern. According to 
Karch (2005), most deaths occur after prolonged drug use, which can induce a series of 
changes at the molecular, cellular, and tissue levels. Potentially lethal myocardial alterations 
include hypertrophy, fibrosis, and microangiopathy and all of these changes favour sudden 
death, possibly through hypertension, arrhythmias, and cardiac infarction (Knuepfer, 2003; 
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Vasica and Tennant, 2002). Darke et al. (2005) found cardiac pathology in 57% of 146 cocaine-
related fatalities, most commonly coronary artery atherosclerosis (39%) and cardiac hypertrophy 
(14%); cerebrovascular pathology was noted in 22% of cases. 
 
<Table 7 about here> 
 
Both the GMR and SMR UK data show that polydrug abuse ingestion was involved in most 
cocaine-related fatalities. This closely mirrors an earlier study looking at amphetamine/ 
methamphetamine and ecstasy deaths reported to NPSAD, where ecstasy fatal ingestion 
seemed to be most typically identified together with cocaine (Schifano et al., 2010), and both 
drugs are frequently associated with the recreational scene (Winstock and Schifano, 2009). Co-
occurrence of two stimulants (i.e. MDMA together with cocaine) might increase, in a synergic 
way, both the dopaminergic and serotonergic stimulation, so that the ‘serotonin syndrome’ is 
more likely to occur (Schifano, 2004). Cocaine/amphetamine users have an increased risk of 
death (Arendt et al., 2011). 
 
Contributory clinical factors described here at post mortem in cocaine fatalities were overall 
consistent with the existing literature, often anecdotal in nature, and reflect a number of issues, 
including: the sympathomimetic action of cocaine (Liaudet et al., 2014); the possible 
idiosyncratic toxic reactions to this drug (Bromley and Hayward, 1988; Chakko and Myerburg, 
1995); and the risk-taking behaviour byof cocaine misusers (Pavarin et al., 2011). These 
findings are similar to those found in respect of ecstasy and amphetamine/methamphetamine 
fatalities (Schifano et al., 2010). 
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CNS suppressants such as opiates (especially heroin/morphine), drugs for 
anxiety/insomniahypnotics/sedatives (principally benzodiazepines) and alcohol contribute 
significantly to UK cocaine-related deaths – whether only with cocaine or with cocaine and other 
drugs. Other medications and ‘recreational’ drugs contribute less to cocaine deaths – but it is 
important to note the contribution played by other stimulants, i.e. ecstasy and amphetamines. In 
22.4% of all NPSAD deaths in which cocaine was implicated in 2005-9, it was the only drug 
implicated. 
 
For NPSAD overall in 1998-2012, there were 11.4 times more PM cases with cocaine and other 
substances than cases with only cocaine mentioned; the ratio for such ‘mentions’ in the cause 
of death field was 4.7. The overall proportion of sole cocaine ‘mentions’ in the cause of death 
during the period 1998-2012 was 17.5% (range 9.6-25.7%). This finding was echoed by the PM 
toxicology findings, where the overall proportion of sole cocaine findings in PM toxicology during 
the period 1998-2012 was 8.1% (range 3.0-19.6%). These results reflect a trend towards poly-
substance abuse; an average of 3.37 substances was found in PM toxicology in 2005-9. 
 
The number of cases where cocaine was found in PM toxicology was 44.5 % (n=4200) higher 
than the number where it was implicated in the cause of death (n=2907). The ratio for 1998-
2012 was 1.44:1.  
 
The clearest feature is that opiates/opioids are involved in most cases (58%), often without 
other substances. This dominant presence of opiates/opioids in cocaine-related DRDs (mostly 
defined here as poisoning/overdoses) mirrors wider patterns evident in European and UK DRDs 
(Burton et al., 2014; EMCDDA, 2015). The large proportion of cocaine-related deaths in the 
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present study involving heroin, methadone or other opioids also echoes that in respect of our 
earlier study of amphetamine/methamphetamine users (Schifano et al., 2010). These are drugs 
with high levels of toxicity in overdose and typically associated with the ‘hard core’ addiction 
scene (Ghodse et al., 2008). This suggests that many cocaine users are problematic and poly-
substance users; both factors increasing the risk of overdose/poisoning and of death. 
 
Alcohol (either alone or together with other drugs) was identified in combination with cocaine in 
about 21% of NPSAD cases in 2005-9. Cocaine and ethanol are commonly consumed at the 
same time (Schifano, 2001). Cocaine is transesterified by liver esterases to cocaethylene, which 
has cocaine-like pharmacologic properties, in the presence of ethanol (Dean et al., 1991). Both 
ethanol and cocaethylene reduce mean cocaine clearance by 47% and 26%, respectively 
(Parker et al., 1996). The effect of cocaine is therefore prolonged and the ‘comedown’ following 
cocaine is diminished (Schifano and Corkery, 2008).  
 
Non-poisoning/overdose cases 
 
Poisonings and somatic deaths overlap so it can be difficult to distinguish between them. For 
most GMRs, including the UK, the mode of use or route of administration of cocaine is not 
known/recorded. The UK SMR (NPSAD) does record such information when available, but is 
dependent on the quality of data submitted. These factors may lead to under-identification of 
somatic cases associated with cocaine use, as the link would only be apparent from evidential 
information or intelligence.  
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In the UK SMR most cocaine-related cases (87%) were ascribed to underlying cause in 2005-9. 
‘General medical condition’ appears to play a large contribution to non-overdose cases, about 
one-third in the UK. This category encompasses a whole range of underlying causes of death 
which might merit closer examination in the future using a finer-grained approach. Some non-
overdose cases due to cocaine are recorded. These are even more likely than poisoning to be 
underestimated, e.g. excited delirium, road traffic accidents (RTAs). Deaths involving accidental 
injury and RTAs also feature as do suicides (often by hanging) in most countries, especially in 
the UK.  
 
Mental and behavioural disorders play a role in UK deaths. For example, in 2011-2 the mortality 
rate for service users in England recorded in the Mental Health Minimum Dataset was 4008 
deaths per 100,000 compared to 1122 deaths per 100,000 in the general population - 3.6 times 
higher (HSCIC, 2013). Premature mortality attributable to illicit drug dependence was calculated 
as Years of Life Lost (YLL) based on cause of death estimates by the Global Burden of Disease 
(GBD) team for the year 2010 (Degenhardt et al., 2013). An estimate of 25,000 YLL due to 
cocaine dependence was indicated, contributing 5.5% of the drug dependence considered. This 
equates to 4290 deaths worldwide each year (i.e. 5.5% of 78,000 deaths p.a. due to illicit drug 
disorders). In the present study, 4% of cocaine poisoning deaths in 2005-9 reported to the UK 
SMR were due to intoxication, dependence, etc. Suicide by regular users of cocaine was found 
by the GBD team to be a significant contributor to the illicit drug burden. In addition, cocaine 
dependence accounted for 6.9 million cases of mental and substance use disorders worldwide 
in 2010 (Whiteford et al., 2013). In Western Europe there were an estimated 640,700 cases with 
a further 62,000 in Central Europe (Degenhardt et al., 2014). 
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At-risk groups 
 
The data from the UK SMR (see Tables 5, 6 and 7) suggest the possibility of five categories of 
cocaine users at greater risk of dying: 
 
(a) those using cocaine in the context of opioid use, especially heroin and methadone 
(Pavarin, 2013; de la Fuente et al., 2014); 
 
(b) those using cocaine with alcohol, as in the ‘champagne’ (Shapiro, 2002; Santos et al., 
2012) style or mode (Roe and Man, 2006);  
 
(c) those using cocaine in the context of psychiatric problems or experiencing psychiatric 
problems consequent to cocaine misuse/abuse (Arendt et al., 2011; Addy et al., 2012) 
(instances of psychiatric medications, i.e. drugs for depressionantidepressants and/or 
drugs for psychosisantipsychotics implicated in death);  
 
(d) those consuming cocaine in the context of recreational drug use, including other 
stimulants (amphetamine, ecstasy), GHB/GBL, ketamine and Novel Psychoactive 
Substances, e.g. in night clubs, discos (Roe and Man, 2006; Home Office, 2012; 
Corkery et al., 2015); and 
 
(e) those with cardiovascular/remaining medical conditions (Cregler, 1989; Gray, 1993; 
Pavarin et al., 2011). 
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Some of these groups are redolent of those identified/described in the British Crime Survey 
(Roe and Man, 2006). A limitation of the profile of users is that it is based on deaths only up to 
2009. If the period was extended not only would there be more cases on which to draw 
conclusions but also one would be able to see if any of the characteristics changed over time, 
especially in response to the emergence of NPS. In this study period (2005-9) the only NPS 
class emerging was piperazines. Since then, other stimulants such as synthetic cathinones and 
cannabinoids have appeared (Schifano et al., 2015).  
 
Toxicological analysis   
 
There may be some types of death where toxicological analysis may not be undertaken or the 
role of psychoactive substances is underplayed because of the main cause of death e.g. 
assaults, suicides (particularly using violent means such as hanging), or accidents (RTAs, 
drowning, accidental injury). Such cases may therefore not be recorded as drug-related let 
alone as cocaine-related. Thus, the data provided her  are likely to underestimate the presence 
of and/or involvement of cocaine in these kinds of unnatural death.  
 
EMCDDA DRD experts consider that guidance is needed on interpretation of post mortem 
toxicology levels to define overdoses/poisonings (Corkery, 2012). There are wide variations in 
levels considered be toxic/fatal/lethal, especially when considering post mortem redistribution. 
These levels can be affected by poly-substance use and metabolism. It is important to know 
fatal levels for sole cocaine deaths. Bertol et al. (2008) suggest that it is not generally possible 
to correlate specific blood/tissue concentrations with toxicity. However, some guidance on post 
mortem toxicology levels and help in the operationalisation of these aspects is available (Lahti 
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et al., 2009; Stephens et al., 2004). Equally important is the need to identify the effect of poly-
substance use on what should be regarded as fatal levels. New challenges in this area are 
posed in monitoring and understanding such deaths because of the growing trend towards 
using multiple stimulants.  
 
Cutting agents 
 
Consideration needs to be taken of the potential contribution to cocaine-related deaths played 
by common cutting-agents found in powder cocaine – and to a lesser extent in ‘crack’. Cutting 
agents include both pharmacologically inactive substances with a similar appearance i.e. 
diluents (e.g. sugars such as mannitol) and adulterants which are pharmacologically active 
components that may alter a drug’s properties. It has been suggested that the addition of 
adulterants to cocaine is to meet increased demand for the drug, they are cheaper alternatives 
to cocaine, and they can be used to increase profits by diluting the final product (Brunt et al., 
2009). Cocaine derivatives such as benzocaine, lidocaine/lignocaine, procaine, as well as 
caffeine, are common examples.   
 
Over the past two decades the following adulterants, which are ‘per se’ associated with levels of 
toxicity (Pawlik et al., 2015), have been found in cocaine seized by law enforcement agencies 
and/or PM toxicological assays in the UK and Western Europe: atropine, benzocaine, caffeine, 
diltiazem, ephedrine, hydroxyzine, levamisole, lidocaine/lignocaine, paracetamol, phenacetin, 
procaine (King, 1997; Brunt et al., 2009; Evrard et al., 2010; Schneider and Meys, 2011).  There 
appear to have been increases in caffeine, diltiazem, hydroxyzine and levamisole since 2007 
but a decrease in lidocaine over the years. The diversity of adulterants in cocaine has increased 
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considerably (Brunt et al., 2009), and up to 14 may be found in one sample (Schneider and 
Meys, 2011). The commonest adulterants in UK seizures in during 2014 were (LGC, 2015): 
powder cocaine – benzocaine, caffeine, creatine, diltiazem, levamisole, lignocaine, paracetamol 
and phenacetin; crack – benzocaine, caffeine, levamisole and phenacetin.  
 
Generally speaking, adulterated cocaine is more likely to give rise to reported adverse effects 
than purer forms (Brunt et al., 2009). However, Brunt et al. (2009) suggest that such reports are 
more likely in relation to diltiazem, hydroxyzine and phenacetin, but not caffeine, levamisole, 
lidocaine/lignocaine and procaine. The possibility of interactions between adulterants and 
cocaine is not well researched. Additional concerns are that: often durations of exposure are 
unknown (Brunt et al., 2009; Evrard et al., 2010); users are unable to detect specific adulterants 
(Evrard et al., 2010); the variable purity level and the wide range of adulterants can lead to 
unpredictable clinical effects (Evrard et al., 2010); and many of these adulterants are prescribed 
for oral ingestion in therapeutic treatment but pharmacokinetic properties such as absorption, 
bio-availability, distribution, metabolism and kinetics may be affected by other administration 
routes (Brunt et al., 2009; Pawlik et al., 2015). If cocaine is insufflated or smoked the 
adulterants will also be incorporated into the lung initially (Pawlik and Mahler, 2013), and may 
result in lung damage or disease (Hollinger, 1993; Kehrer and Kacew, 1985). Lidocaine, for 
example, may cause pulmonary parenchymal damage, and levamisole’s metabolite – aminorex 
– causes pulmonary hypertension (Hollinger, 1993). 
 
Limitations 
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Detailed demographic and other information are not published by the UK GMRs in respect of 
specific substances. Only the Scottish GMR has access to toxicological information, and even 
that is very limited.  However, in recent years the Scottish DRD database has linked GMR data 
with information regarding toxicology and pathology and publishes some more detailed analysis 
(Barnsdale et al., 2016). A similar approach could be used to advantage in other parts of the 
UK. 
 
Although the UK SMR results suggest that most cocaine-related deaths are also opiate/opioid-
related and/or polydrug poisoning cases, it is likely that some cocaine-related fatalities will be 
missed by the DRD Key Indicator data based on UK GMR data. This is because UK GMRs do 
not typically have access to toxicological information and up to 12% of all drug poisonings 
fatalities in the UK recorded by the GMRs are recorded as multiple/substances 
intoxications/overdoses without specific substances being recorded on the death certificate 
(ONS, 2014). 
 
Limited data were available when the original study was conducted. Looking at SMR data over 
a longer period would provide a larger dataset for analysis and facilitate an examination of 
trends in characteristics of both individuals experiencing cocaine-related fatalities and also of 
the mechanisms/causes of death an any change in contributing factors, especially with regard 
to the consumption of other psychoactive substances (including alcohol) and the adulterants 
used as cutting agents. Also an examination of mortality trends splitting cases into ones 
involving opiates/opioids vs. other substances may reveal other issues of interest. 
 
Conclusions  
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GMR information provides some indications of long-term trends and possible numbers of cases 
of deaths related to cocaine, as does UK SMR data. The latter is beneficial in providing a more 
in-depth understanding of the characteristics of decedents and the nature of their deaths. As 
with other projects looking at DRDs, the EMCDDA project faced problems arising from the 
different nature, purposes, roles and type of data recorded by individual registries, especially 
SMRs. The level of detail, use or not of ICD codes and other information to identify relevant 
cases, as well as varying selection criteria are impacted by those differences. In turn, this 
affected the quality and type of data submitted. However, this project gives pointers for where 
further refinement could be targeted. Guidance is needed on the PM toxicology levels to define 
overdoses/poisonings. There are wide variations in levels considered toxic/fatal/lethal. These 
levels can be affected by poly-substance use and metabolism in terms of blood levels. It is 
important to know levels for sole cocaine and poly-substance deaths. The provision of such 
guidance across the EU and UK may help improve case-identification both prospectively and in 
any future retrospective data analyses.   
 
This analysis of  fatalities that did not arise through overdose suggests that it would be valuable 
to examine more closely those cases ascribed to ‘general medical conditions’, ‘cardiovascular 
and other issues’, etc. The scientific medical literature is increasingly featuring small-scale case-
study or anecdotal reports of conditions associated with the acute and chronic use of cocaine. 
Mena et al. (2013) found a considerable increase in the numbers of cocaine-related hospital 
episodes and emergency admissions since the end of the 1990s in the countries that reported 
the highest number of episodes, numbers peaking around 2007/8 in Spain and the UK. This 
underlines the importance of seeking a more accurate picture of the numerical extent of such 
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conditions and a fuller understanding of what conditions and diseases are caused, and how, by 
cocaine use. Other areas that could also be examined in the future include: the role of cocaine 
in deaths involving accidental injuries, road traffic accidents, and suicides - especially by 
hanging. There is anecdotal material, including from the UK, to suggest that stimulants (such as 
cocaine, MDMA, amphetamine, and more recently methcathinones) are often consumed by the 
decedents in such cases; published literature on these aspects is very limited, e.g. Rajs & 
Fugelstad (1999), Oyefeso et al. (2006),  
 
Further research is needed on the clinical implications of cocaine misuse in the context of 
polydrug intoxication – especially with regard to possible changes over time in the co-
ingestion/administration of opioids on the one hand and stimulants on the other, with deaths 
where cocaine was directly related to death and other cases where it was just found at post 
mortem being compared, and should also specifically address the issue of possible individual 
psychobiological/genetic vulnerability to deaths caused by cocaine (Schifano and Corkery, 
2008). The role of adulterants in cocaine in contributing to death also warrants further 
investigation.  
 
In conclusion, cocaine-related DRDs have become an important feature of drug-related 
mortality in the UK and Europe generally - perhaps accounting for more than 1000 deaths each 
year. These are likely to continue to be so in the future, due to the large number of chronic and 
problematic users. There are at least 42,000 cocaine/crack users seeking treatment in the UK in 
recent years (personal communications from Public Health England on 16 January and 25 
February 2015 to lead author; ISD Scotland 2014; DHSSPSNI, 2014; Welsh Government & 
NHS Wales, 2014). Furthermore, we have noted in the UK increasing quantities of cocaine 
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powder and crack being seized by law enforcement agencies, rising purity levels for street 
cocaine and crack, and increasing presentations for treatment by primary cocaine users. All of 
these would suggest the potential for continuing or rising numbers of deaths due to cocaine use.  
Indeed, there are indications that cocaine-related deaths across the UK are on the increase 
again (NISRA, 2016; NRS, 2016; ONS, 2016). It is necessary to understand the nature and 
extent of this phenomenon. Some core commonalities have been observed in respect of the 
UK, but more information is needed, especially since they accounted for 5% of all UK poisoning 
deaths registered in the period 1998-2012, an average of 174 deaths each year. The data and 
information presented in this paper and the EMCDDA project (Corkery, 2012) provides the first 
insights into the nature and possible extent of the phenomenon of cocaine-related DRDs in the 
UK and Europe.   
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Figure 1: Medical Certificate of Death used in England and Wales 
 
Source: Rooney and Smith, 2000. Reproduced with permission. 
Page 55 of 68
http://mc.manuscriptcentral.com/jop
Journal of Psychopharmacology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Figure 2: Trends in UK cocaine-related DRDs (any mention): actual numbers in 1998–
2012, based on SMR and GMR and reported for cocaine mentioned in the 
cause of death (COD), or identified in post mortem (PM) 
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Figure 3: Results of Joinpoint analyses for UK cocaine-related death trends 1998-2012 
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SMR Post Mortem Toxicology Sole Mention 
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Table 1: Cocaine-related deaths recorded by UK GMRs and SMR, 1998–2012 
 
Case definition 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 
GMR cause of death 
Any  mention 69 100 88 117 161 161 192 221 224 246 325 264 198 171 191 2728 
       Of which as sole 
substance 
28 32 40 41 45 47 51 64 83 92 101 79 63 37 42 845 
 Ratio of any/sole 2.46 3.13 2.20 2.85 3.58 3.43 3.76 3.45 2.70 2.67 3.22 3.34 3.14 4.62 4.55 3.23 
Sole as proportion of any 
(%) 
 
40.6 
 
32.0 45.5 35.0 28.0 29.2 26.6 29.0 37.1 37.4 31.1 29.9 31.8 21.6 22.0 31.0 
SMR cause of death 
 Any  mention 83 136 133 191 263 240 167 222 206 321 267 218 156 167 137 2907 
Of which as sole 
substance 
8 19 17 19 30 23 30 55 53 61 67 41 33 25 29 510 
 Ratio of any/sole 10.38 7.16 7.82 10.05 8.77 10.43 5.57 4.04 3.89 5.26 3.99 5.32 4.73 6.68 4.72 5.70 
Sole as proportion of any 
(%) 
 
9.6 14.0 12.8 9.9 11.4 9.6 18.0 24.8 25.7 19.0 25.1 18.8 21.2 15.0 21.2 17.5 
SMR post mortem mentions 
 Any mention 83 136 135 97 275 254 281 357 361 476 476 392 271 264 242 4100 
Of which as sole 
substance 
8 19 16 19 27 21 27 37 36 36 32 21 16 8 10 333 
Ratio of any/sole 10.38 7.16 8.44 10.37 10.19 12.10 10.41 9.65 10.03 13.60 14.88 18.67 16.94 33.00 24.20 12.31 
Sole as proportion of any 
(%) 
 
9.6 14.0 11.9 19.6 9.8 8.3 9.6 10.4 10.0 7.6 6.7 5.4 5.9 3.0 4.1 8.1 
Notes: GMR is year of registration; SMR is year of death 
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 2
Table 2: Summary of Joinpoint analyses for UK cocaine-related deaths, 1998-2012 
 
Dataset Period 1 APC 1 Period 2 APC 2 P value Significant at 
0.05 level 
GMR Cause of Death 
Any 1998-2008 +14.75* 2008-2012 -14.65* 0.3128889 Yes 
Sole 1998-2008 +13.38* 2008-2012 -21.81* 0.4004444 Yes 
SMR Cause of Death 
Any 1998-2002 +30.42* 2002-2012 -4.02 0.0857778 Yes 
Sole 1998-2007 +22.11* 2007-2012 -18.09* 0.8853333 Yes 
SMR Post Mortem toxicology 
Any  1998-2007 +20.77* 2007-2012 -14.30* 0.9742222 Yes 
Sole 1998-2007 +14.90* 2007-2012 -28.40* 0.4102222 Yes 
Notes: APC = Annual Percent Change; * = p <0.05 
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 3
Table 3: Demographic characteristics of UK SMR cocaine-related DRDs 2005-9 
 
Characteristic Category Sole Any 
  Number % Number % 
Total  277 100.0 1234 100.0 
Gender Male 241 87.0 1042 84.4 
 Female 36 13.0 192 15.6 
Age-group (years) < 15 0 0.0 0 0.0 
 15-24 40 14.4 183 14.8 
 25-34 105 37.9 506 41.0 
 35-44 97 35.0 394 31.9 
 45-54 28 10.1 127 10.3 
 55-64 6 2.2 21 1.7 
 65 & over 1 0.4 3 0.2 
Ethnicity White 187 67.5 856 69.4 
 Black 26 9.4 54 4.4 
 Indian Sub-Continent 10 3.6 25 2.0 
 Other 8 2.9 39 3.2 
 Not known 46 16.6 260 21.1 
Employment status Unemployed 51 18.4 438 35.5 
 Employed 143 51.6 478 38.7 
 Childcare/houseperson 5 1.8 17 1.4 
 Student/pupil 4 1.4 18 1.5 
 Retired/invalidity/sickness 5 1.8 22 1.8 
 Other 1 0.4 8 0.6 
 Not known 68 24.5 253 20.5 
Living arrangements With others 143 51.6 553 44.8 
 Alone 88 31.8 397 32.2 
 No fixed abode 1 0.4 33 2.7 
 Other 7 2.5 40 3.2 
 Not known 38 13.7 211 17.1 
Known drug-using history Yes 115 41.5 656 53.2 
 No 44 15.9 146 11.8 
 Not known 118 42.6 432 35.0 
Injecting status Yes 9 3.2 83 6.7 
 No 34 12.3 100 8.10 
 Not known 234 84.5 1051 85.2 
Age at death (years) Mean 34.67  34.29  
 Minimum 16.19  15.59  
 Maximum 67.23  81.33  
 Std. Dev. 9.269  9.045  
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 4
Table 4: Principal underlying causes of death in UK SMR cocaine-related DRDs 2005-9  
 
Cause of death Sole Any 
 Number % Number % 
Accidental poisoning 211 76.2 979 79.3 
Intentional poisoning 7 2.5 27 2.2 
Poisoning of undetermined intent 9 3.2 76 6.2 
Other overdoses 1 0.4 2 0.2 
Hanging 10 3.6 36 2.9 
Asphyxiation/aspiration of gastric contents 0 0.0 2 0.2 
Mental & behavioural disorders 21 7.6 51 4.1 
Injuries 1 0.4 10 0.8 
Drowning 0 0.0 2 0.2 
Traffic accidents 0 0.0 5 0.4 
Jumps/falls from height  0 0.0 1 0.1 
Pneumonias & other lung conditions 1 0.4 2 0.2 
Cardio-respiratory failure/arrest & cardio-vascular problems 10 3.6 21 1.7 
GI/Hepatic/renal problems 0 0.0 2 0.2 
Intestinal/alimentary obstruction 2 0.7 2 0.2 
Epileptic seizures 2 0.7 2 0.2 
Other effects on brain 1 0.4 4 0.3 
Other 1 0.4 2 0.2 
Unascertained 0 0.0 8 0.6 
N 277 100.0 1234 100.0 
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 5
Table 5: Principal substances implicated in UK SMR cocaine-related DRDs 2005-9 
 
Substance Number % 
Cocaine - any 1234 100.0 
Cocaine - only 277 22.4 
Alcohol 368 29.8 
Heroin/morphine 594 48.1 
Methadone 192 15.6 
Other opiates/opioid analgesics 153 12.4 
Drugs for anxiety/insomniaHypnotics/sedatives (mostly benzodiazepines) 220 17.8 
Drugs for depressionAnti-depressants 108 8.8 
Drugs for psychosisAnti-psychotics 21 1.7 
Anti-histamines 8 0.6 
Anti-epileptics 3 0.2 
Anti-Parkinson’s 1 0.1 
Amphetamines 56 4.5 
Ecstasy/MDMA 62 5.0 
GHB/GBL 14 1.1 
Ketamine 14 1.1 
Novel Psychoactive Substances (i.e. piperazines)* 13 1.1 
Note: Piperazines were the only class of Novel Psychoactive Substances  
present in this period. 
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 6
Table 6: Common combinations of substances implicated in UK SMR cocaine-related 
DRDs 2005-9 
 
Substance combination Number % 
Alcohol & heroin/morphine 186 15.1 
Alcohol & any opiate/opioid 229 18.6 
Any opiate/opioid 718 58.2 
Any medication (exc. opiates/opioids) 129 10.5 
Any medication (exc. opiates/opioids) & alcohol 53 4.3 
Any opiate/opioid & drugs for anxiety/insomniahypnotics/sedatives 182 14.7 
Any opiate/opioid & drugs for anxiety/insomniahypnotics/sedatives & alcohol 62 5.0 
Any drugs for anxiety/insomniahypnotics/sedatives & alcohol 86 7.0 
Any recreational drug (amphetamines, ecstasy, ketamine, GHB/GBL, NPS, etc.) 137 11.1 
Any recreational drug (amphetamines, ecstasy, ketamine, GHB/GBL, NPS, etc.) & alcohol 44 3.6 
Amphetamines and/or ecstasy 109 8.8 
Amphetamines and/or ecstasy & alcohol 35 2.8 
Notes: N = 1234. Totals for individual categories should not be added together.  
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 7
Table 7: Presence of contributing factors associated with cocaine mono-intoxication 
acute poisoning in UK SMR cases, 2005-9 
 
36 (13%) cases: pre-existing cardiovascular/cardiopulmonary conditions, which may lead to other complications and 
causes of death (e.g. ischaemic heart disease; coronary artery thrombosis; coronary thrombosis; thrombosis of left 
anterior descending coronary artery; coronary artery disease; coronary artery atheroma; myocardial fibrosis; 
hypertension; myocardial infarction; cardiomegaly; cardiomyopathy; left ventricular hypertrophy; left & right ventricular 
hypotrophy; myocardial hypertrophy; dissecting aortic aneurysm; necrosis) 
23 (8%) cases: events possibly related to at-risk behaviours whilst on cocaine leading to external causes of death (e.g. 
immersion; head or multiple injuries i.e. road traffic accidents; hanging; cardio-respiratory arrest during restraint; 
intestinal obstruction in body-packers; toxicity in body-packers; mechanical obstruction of upper airway by foreign 
bodies => asphyxia) 
8 (3%) cases: associated infections (e.g. bronchopneumonia; aspiration pneumonia; COPD; pneumonia; acute 
bronchitis; adult respiratory distress syndrome; myocarditis) 
8 (3%) cases: pre-existing chronic medical conditions/natural disease (e.g. fatty liver change; alcohol liver disease; 
epilepsy/grand mal seizure; pulmonary hypertension & Cor Pulmonale) 
In 62 (22%) cases, only cocaine and its well-known medical consequences were mentioned as the cause of death, 
including: myocardial infarction; cardio-respiratory failure/arrest, (acute) cardiac arrest/failure, sudden (cardiac) death; 
left ventricular failure; cardiac/ myocardial ischaemia/insufficiency; thromboembolism, thrombosis; myocardial damage, 
fibrosis; cardiac arrhythmia/disrhythmia; cerebral infarction, hypoxic brain damage/cerebral hypoxia, intracerebral 
haemorrhage; pulmonary oedema; pulmonary haemorrhage; aspiration of gastric contents/aspiration, asphyxia; 
pancreatitis; gastro-intestinal bleed/haemorrhage; renal failure.  
154 (56%) cases: cocaine intoxication, overdose, poisoning, toxicity, fatal misuse, etc. 
Notes: N = 277. More than one condition can be recorded in the medical cause of death; therefore totals for individual 
categories should not be added together. Cocaine was the only drug mentioned in the cause of death. 
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